Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Neurofibroma is described in the packet as an intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. The packet lists neurofibroma (WHO grade I), benign neurofibroma, and NFIB among its synonyms. The packet does not supply prevalence estimates, age of onset, or gene associations.
According to the packet's definition, a neurofibroma usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. The definition states that patients with neurofibromatosis type 1 present with multiple masses. No phenotype annotations or characteristic findings are supplied in this packet, so a fuller symptom profile is not certified here. The packet lists subtypes that include plexiform neurofibroma, cellular neurofibroma, atypical neurofibroma, and epithelioid neurofibroma.
The packet's definition describes neurofibroma as a neoplasm composed of perineurial-like fibroblasts and Schwann cells arising from nerve tissues and neural sheaths, and notes an association with neurofibromatosis type 1. The packet lists no associated genes and supplies no inheritance pattern, so the genetic basis is not certified here.
Diagnostic methods and criteria are not certified in this packet.
Treatment coverage is not certified in this packet. The packet supplies no approved treatments, foundational therapies, or management text for neurofibroma.
89 trials found
Prognosis is not certified in this packet, which supplies no natural history information. The packet's definition states that neurofibromas arising from major nerves, and plexiform neurofibromas, are precursor lesions to malignant peripheral nerve sheath tumors.
The packet records 78 ClinicalTrials.gov records related to neurofibroma and provides ten in detail, most sponsored by the National Cancer Institute. The detailed records include NCT02390752, a Phase 1 study of pexidartinib in children and young adults with refractory leukemias and solid tumors, including neurofibromatosis type 1 associated plexiform neurofibromas (recruiting); NCT06222203, a surveillance study for malignant transformation of neurofibromatosis type 1 related peripheral nerve sheath tumors (recruiting); NCT06961565, a Phase 1 study of PAS-004 in adults with neurofibromatosis type 1 and plexiform neurofibromas sponsored by Pasithea Therapeutics (recruiting); and NCT05581511, a Johns Hopkins University natural history study of cutaneous neurofibromas (active, not recruiting). The detailed records also include studies in NF2-related schwannomatosis, low grade glioma, and juvenile myelomonocytic leukemia. The packet's research landscape digest classifies 306 publications, with case reports and case series the dominant type. No patient organizations are supplied in this packet.
Data assembled from 4 of 12 sources · Last updated Nov 17, 2026, 3:00 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center